Depression

Independence Blue Cross has increased local provider options by 47% since 2022, and now offers additional mental health and substance abuse services.

The FDA rejected an application to approve MDMA, also known as ecstasy, as a treatment for PTSD. Next up among the psychedelics vying for FDA approval: psilocybin for treatment resistant depression.

Cost and lack of access were two of the most common reasons given in new survey.

Biotech companies and researchers are investigating whether psychedelics could be used to treat a variety of mental health problems, including post-traumatic stress disorder and depression.